Overview

EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators aim to investigate whether incorporating on-treatment EBV DNA surveillance for monitoring tumor responses to treatment and for guiding individuliased treatment adaptation can improve prognosis in nasopharyngeal carcinoma patient . For patients with detectable EBV DNA after one cycle of IC, which then drops to undetectable levels during the following IC cycles (intermediate responders/intermediate relapse risk), the investigators aim to investigate whether additional adjuvant metronomic capecitabine would benefit this subgroup. For patients with detectable EBV DNA after three cycles of IC or with EBV DNA bounce during the induction phase (insensitive to IC/high relapse risk), the investigators aim to investigate whether concurrent administration of anti-PD-1 therapy during the following treatment phases (including concurrent phase and adjuvant phase) can benefit this subgroup.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
First People's Hospital of Foshan
National Cancer Centre, Singapore
Wuzhou Red Cross Hospital
Treatments:
Capecitabine
Criteria
Inclusion Criteria:

1. Newly diagnosed, pathologically proven World Health Organization (WHO) type II/III
untreated LANPC;

2. LANPC (except T3N0, according to the 8th edition of the AJCC/UICC clinical staging
system);

3. Age at diagnosis: 18-65 years;

4. Eastern Cooperative Oncology Group (ECOG) score: 0-1

5. Receiving recommended three cycles of induction chemotherapy (IC)
(gemcitabine-cisplatin [GP] regimen);

6. Pre-treatment and post-IC1 cell-free Epstein-Barr virus (cfEBV) DNA > 0 copy/mL;
systemic cfEBV DNA monitoring during IC phase for risk stratification;

7. Normal hematic, liver, and kidney function: hemoglobin (HG) > 90 g/L; neutrophil > 1.5
× 109/L; platelet > 100 × 109/L; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal
(ULN); alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 × ULN;
alkaline phosphatase (ALP) ≤ 2.5 × ULN; creatinine clearance (Ccr) ≥ 60 mL/min;

8. Female subjects capable of becoming pregnant agree to use reliable contraceptive
measures from screening to 1 year after treatment;

9. Patients will be required to sign informed consent forms and be willing and able to
comply with the requirements for visits, treatment, laboratory tests, and other
research requirements stipulated in the research schedule.

Exclusion Criteria:

1. Receiving surgery, target therapy, and/or immunotherapy during or before induction
phase;

2. Hepatitis B surface antigen-positive [HBsAg(+)],hepatitis B virus (HBV) DNA > 1×103
copy/mL; hepatitis C virus (HCV) antibody(+);

3. Other previous or concurrent malignant tumors, except adequately treated non-melanoma
skin cancer, cervical carcinoma in situ, and thyroid papillary cancer;

4. Pregnant or lactating women (a pregnancy test should be considered for fertile women
with an active sex life);

5. Previously treated with radical radiotherapy (RT), except non-melanoma skin cancers
outside intended RT treatment volume;

6. Uncontrolled heart disease, e.g.: 1) Heart failure, Hew York Heart Association (NYHA)
level ≥ 2; 2) unstable angina; 3) myocardial infarction in the past 1 year; 4)
supraventricular or ventricular arrhythmia requiring treatment or intervention;

*For patients recruited to Arm II, the additional exclusion criteria are:

7. Active, known, or suspected autoimmune disease (including, but not limited to,
uveitis, enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism,
hypothyroidism, and asthma requiring bronchiectasis). Exceptions are type I diabetes
mellitus, hypothyroidism requiring hormone replacement therapy, and skin disorders
requiring no systemic treatment (e.g., vitiligo, psoriasis, alopecia);

8. Received live vaccine within 1 month before treatment initiation;

9. Allergy to macromolecular protein preparations, or any component of sintilimab;

10. Human immunodeficiency virus (HIV)-positive or diagnosed with Acquired Immune
Deficiency Syndrome (AIDS).